NCT05519865 2026-04-20
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
Chipscreen Biosciences, Ltd.
Phase 2 Completed
Chipscreen Biosciences, Ltd.
RemeGen Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
BeOne Medicines
ImmunityBio, Inc.
Tianjin Medical University Cancer Institute and Hospital
BeOne Medicines
Novartis
Jiangsu Alphamab Biopharmaceuticals Co., Ltd